Aims: This study aimed to identify the long-term clinical outcomes and prognostic factors of patients with SLE-associated PAH confirmed by right heart catheterization.
Introduction
Connective tissue disease (CTD) is a major cause of pulmonary arterial hypertension (PAH) and causes 25 .3% of PAH and 50.7% of associated PAH [1] . However, the underlying CTD varies between different populations. Although systemic sclerosis (SSc) is widely recognized as the major underlying cause of CTD-associated PAH in the Western world [2, 3] , systemic lupus erythematosus (SLE)-associated PAH is most commonly reported in Asian countries [4, 5] , especially in China, due to its higher prevalence of SLE than that in other ethnicities [6] . Notably, according to a meta-analysis of studies from the US [2, 7] , UK [8] , Japan [9] and China [4] , the 5-year pooled survival rate was 68% for patients with SLE-associated PAH [10] . Compared with the 5-year survival rate for patients with SLE (92-94%) [11, 12] , the clinical outcome of SLE patients is dramatically worsened after developing PAH [13] . However, only three studies (including 124 patients) meeting the eligible criteria were utilized to calculate the 5-year pooled survival rate with a huge heterogeneity (I 2 = 52.7%) [10] . Thus, a large, multicenter study is required to determine the long-term prognosis of patients with SLE-associated PAH.
The Chinese SLE Treatment and Research Group (CSTAR) was established in 2009 to collect data from
Chinese patients with SLE and was further extended with the formation of the Chinese Rheumatism Data Center (CRDC), which is directed by the National Health and Family Planning Commission of the People's
Republic of China [14, 15] . Based on the CSTAR registry, we determined the prevalence of PAH among
Chinese patients with SLE [16] . Herein, we identified the long-term clinical outcomes, including mortality and treatment goal achievement (TGA), and related prognostic factors of patients with SLE-associated PAH confirmed by right heart catheterization (RHC) and also demonstrated the association between mortality and TGA.
Methods

CSTAR-PAH cohort
The CSTAR registry is a nationwide registry involving 104 rheumatology centers covering 30 provinces in China [15] . In total, 14 referral centers of CTD-associated PAH were qualified as patients enrollment classification criteria [17] and the diagnosis of PAH based on RHC defined as the mean pulmonary arterial pressure (mPAP) ≥ 25 mmHg at rest, pulmonary arterial wedge pressure (PAWP) ≤ 15 mmHg, and pulmonary vascular resistance (PVR) > 3 Wood units [18] . Patients with other types of pulmonary hypertension revealed by a pulmonary function test (PFT) showing total lung capacity (TLC) < 60% and ventilation perfusion scintigraphy (V/Q) or computed tomographic pulmonary angiography (CTPA) showing pulmonary thromboembolism were excluded. Patients with overlapping CTD, such as SSc, or other CTDs were also excluded. Application of PAH guidelines [18, 19] and a census-based SLE-associated PAH treatment regimen [20] were as well required as inclusion criteria. This study was approved by the institutional review board, and we obtained informed consent from each patient.
Data collection
The time of recruitment (baseline) was defined as the time of SLE-associated PAH diagnosis confirmed by RHC. At baseline, we collected demographic information and medical history and performed the physical examination, laboratory evaluations, and transthoracic echocardiography (TTE). Data collected at baseline included age; gender; onset of SLE and PAH; organ involvement; SLE Disease Activity Index (SLEDAI) [21] ; WHO functional class (WHO FC); 6-minute walking distance (6MWD); levels of serum brain natriuretic peptide (BNP) and N terminal-pro brain natriuretic peptide (NT-proBNP); anti-U1RNP status;
antiphospholipid antibody status; TTE and RHC parameters (which were reviewed by independent cardiologists), including mean pulmonary arterial pressure (mPAP), pulmonary arterial wedge pressure (PAWP), pulmonary vascular resistance (PVR), cardiac output (CO), cardiac index (CI), and right atrial pressure (RAP); and treatment regimen. The duration of SLE was defined as the time span from the diagnosis of SLE to the diagnosis of SLE-associated PAH by RHC (baseline). Serositis was defined as pleuritis/pleural effusion and/or pericarditis/pericardial effusion detected by TTE, chest X -ray or chest computerized tomography scan [17] .
Follow-up
A comprehensive follow-up evaluation of every patient was recorded and reported at least once a year.
These measures included WHO FC, 6MWD, serum BNP, serum NT-proBNP, and TTE. Treatment regimens were also recorded. Death, causes of death, hospitalization due to disease deterioration, disease-related transplantation or atrial septostomy were also recorded and reported to the database.
Outcomes
The primary end point was death from any cause. Mortality was ascertained from PAH center records and the national population tracking system. The exploratory experimental end point was achieving the integrated treatment goal recommended by the European Society of Cardiology (ESC) and the European
Respiratory Society (ERS) [19] . Treatment goal was defined as achieved when all of the following four aspects were reached, including: 1) clinical symptoms: no signs of right heart failure, syncope or progression; 2) WHO FC I or II, or 6MWD > 380-440 m; 3) serology: BNP < 50 ng/L or NT-proBNP < 300 ng/L; and 4) cardiac imaging: normal right atrial area according to echocardiography. For socioeconomic reasons in our country, hemodynamic parameters were not available in every follow-up visit and therefore were not included in evaluating TGA in our study. TGA was ascertained according to the follow-up date reported by each PAH center prior to the course of data analysis.
Statistical Analyses
Quantitative data are described as the means and standard deviations. Non-quantitative data are described as counts and percentages. Cumulative probabilities of survival and not achieving the treatment goal were calculated with the Kaplan-Meier estimator. Further comparisons were performed with a log-rank test. The Kaplan-Meier survival curves comparing patients with TGA and without TGA were plotted by the method proposed by Simon and Makuch [22] for time-dependent covariates. All-cause mortality was used in survival statistics. Follow-up time was calculated from the date of initial diagnostic RHC. Baseline characteristics between patients with and without clinical outcomes (death and TGA) were compared.
Baseline factors with clinical significance, including age at recruitment, gender, clinical features, RHC parameters, TTE parameters and treatment selection were analyzed by univariate Cox regressions. The cutting-offs of CI and 6MWD were based on the previous studies and guidelines [18, 19] . Considered that there is no widely recognized cutting-off of PVR, we did an outcome-oriented statistical analysis for cut-point determination by the method proposed by Contal and O'Quigley [23] , and used 12 WU as the cutoff in our study. Other parameters, including NT-proBNP, BNP and RAP were firstly dichotomized according to tertiles, and then used in the Cox regression. As TGA was a time-dependent covariate, we used time-dependent Cox regression, in order to avoid immortal time bias. Variables with clinical relevance selected by univariate analysis, including age, gender, and others, were further subjected to multivariate analysis. The proportional hazard assumption based on the Schoenfeld residuals was tested. P values < 0.05 were considered significant. Data analyses were conducted with SPSS 19.0 (SPSS Inc., Chicago, IL, USA) and R software (www.r-project.org).
Results
Baseline characteristics of patients with SLE-associated PAH
In total, 310 patients with RHC-confirmed SLE-associated PAH were enrolled in our study ( Table 1 ). The mean duration of SLE was 4.4 ± 5.4 years. A total of 51.7% patients were WHO FC I or II, and the mean mPAP was 46.5 ± 12.1 mmHg. 99.4% and 92.6% patients were treated with glucocorticoid and immunosuppressant therapy, respectively. A total of 69.4% of patients were receiving PAH medication:
56.7% received endothelin receptor antagonists (ERA), 58.1% received phosphodiesterase inhibitors (PDE5-I), and 7.0% received prostacyclin analogues (PG). Among the 310 recruited patients, 282 patients with confirmed mortality statuses were included in the survival analysis, and 263 patients with full follow-up data were included in the TGA study ( Figure 1 ). The maximum follow-up duration was 107.5 months, and the median follow-up was 24.0 months.
Survival and predictors of mortality for patients with SLE-associated PAH
During the follow-up, 42 (14.9%) deaths occurred. No PAH-related transplantations or atrial septostomies occurred. The 1-, 3-and 5-year survival rates for patients with SLE-associated PAH were 92.1%, 84.8%
and 72.9%, respectively ( Figure 2A ). The mean survival time was 7.0 years.
Baseline characteristics between survivors and non-survivors were compared (Supplementary Table 1 ).
According to the univariate COX analysis, the following baseline factors were associated with mortality (Table 2) Relationship between TGA and death TGA was identified as a factor positively associated with survival in univariate time-dependent Cox regression (HR = 0.18, 95% CI: 0.05 to 0.59, P = 0.005). We then compared the cumulative survival rates between patients who achieved the treatment goal and patients who did not ( Figure 3 ). The cumulative survival rate was significantly higher for patients who achieved TGA (P = 0.002).
TGA and prognostic factors of TGA for patients with SLE-associated PAH
As the secondary exploratory end point of our study, we identified the TGA status of individual patient according to the follow-up data. Among them, 115 (43.7%) patients achieved the treatment goal, and their 1-, 3-and 5-year TGA rates were 31.5%, 53.6% and 62.7%, respectively ( Figure 4A ). The median time from baseline to TGA was 2.5 years. Baseline characteristics were compared between patients who reached the treatment goals and patients who did not (Supplementary Table 2 smaller RV diameter were associated with TGA (Table 3) . After adjusting for the effects of multiple covariates, baseline serositis (HR = 1.99, 95% CI: 1.27 to 3.11, P = 0.003), 6MWD > 380 m (HR = 2.12, 95% CI: 1.22 to 3.68, P = 0.008) and CI ≥ 2.5 L/min×m 2 (HR = 2.14, 95% CI: 1.26 to 3.62, P = 0.005)
were identified as independent prognostic factors of TGA (Table 3) .
Patients with serositis at baseline had better TGA after intensive immunosuppressive therapy
We hypothesized that patients with serositis at baseline would respond better to intensive immunosuppressive therapy (IST), defined as the therapy with one or more immunosuppressants, including cyclophosphamide, mycophenolate mofetil, cyclosporine A and tacrolimus, than those without serositis at baseline. There were no significant differences in baseline characteristics between patients on IST and those on only hydroxychloroquine (HCQ) therapy when stratified by baseline serositis (Supplementary Table 3) . Notably, when comparing TGA between the two therapeutic groups, patients with baseline serositis were more likely to reach TGA after IST compared to non-IST recipients (HR = 2.47, 95% CI: 1.21 to 4.17, P = 0.013), which was not seen in those without baseline serositis ( Figure 5 ).
Discussion
We identified the prognostic factors for patients with SLE-associated PAH based on a multicenter cohort with RHC-based diagnoses. All-cause mortality and TGA were set as the long-term and medium-term clinical end-points, respectively. The 1-, 3-and 5-year survival rates of patients with SLE-associated PAH were 92.1%, 84.8% and 72.9%, respectively. The 1, 3, and 5-year survival rates of 1494 SLE patients recruited during the same time period were 98.3%, 96.9% and 95.7% respectively in China (unpublished data). The survival rates of SLE-associated PAH are higher than those calculated in the previous meta-analysis (1-year 88%, 3-year 81%, 5-year 68%) [10] . In a recent French cohort, the 1-, 3-and 5-year survival rates were 94.1%, 89.4% and 83.9% [24] . There may be a population difference regarding prognosis; however, time-lead bias, disease severity, therapeutic strategy, and the study design should also be considered. According to univariate and multivariate analyses, baseline CI < 2.5 L/min×m 2 was an independent predictor of mortality. Our study, consistent with the conclusions of studies on idiopathic PAH and SSc-associated PAH, confirmed that heart function, represented by CI, is critical to the clinical outcomes of patients with SLE-associated PAH [25] [26] [27] . Preservation or improvement of heart function may become the priority of clinicians in the management of SLE-associated PAH, which will need to be proven in future studies.
Treat-to-target, defined as a therapeutic strategy aiming to treat patients to a goal and improve disease outcome, is increasingly accepted in disease management. A treat-to-target strategy of SLE has been recommended by an international task force, which asserted that complete remission is the main target of SLE [28] . With regard to the heterogeneity of SLE, the treatment goal may vary in situations with different organ involvement [29] . An integrated criterion with multiple parameters, including WHO functional class, symptom, serological, echocardiographic and RHC parameters, was recommended as treatment goals for patients with PAH by ESC/ERS [19] . Although the goal-orientated treatment approach has not been fully validated, several studies have shown recently that PAH patients in a "low-risk" group showed a decreased mortality risk [30] [31] [32] . Although RHC is a relatively direct and accurate way of evaluating PAH, RHC cannot be performed at every follow-up visit due to its invasive nature and to socioeconomic factors in our country. Thus, TGA without RHC parameters was defined as the exploratory secondary end point in our study, and it was favorably associated with survival among patients with SLE-associated PAH. Our study demonstrated that TGA was associated with the long-term survival and that TGA could be a target in the management of SLE-associated PAH. The long-term survival of patients meeting different numbers of treatment goal at specific time points need to be further compared. The 1-, 3-and 5-year TGA rates were 31.5%, 53.6% and 62.7%, respectively. Baseline 6MWD ≥ 380 m and CI ≥ 2.5 L/min×m 2 were identified as predictors of TGA among patients with SLE-associated PAH in our study, indicating that heart function is also crucial in the response to treatment and to even achieving the treatment goal.
Notably, baseline serositis was newly identified to predict TGA in our study. It has been reported in our previous study that SLE disease activity scores were significantly higher in patients with serositis, and pulmonary arterial hypertension was significantly associated with serositis in patients with SLE [33] . Here, we found that indicators of heart failure, such as WHO FC, CI and RAP, had no significant differences in SLE-associated PAH patients with vs. without serositis (data not shown), indicating that inflammation may be the major mechanism leading to serositis in patients with SLE-associated PAH in our study. This result raised the question of whether patients with high SLE disease activity, indicated by baseline serositis, could benefit from immunosuppressive therapy and achieve better clinical outcomes. Therefore, a further stratification analysis was conducted. It showed that patients with baseline serositis were more likely to reach TGA after intensive immunosuppressive therapy (IST) than those without IST, while the same phenomenon was not shown in patients without baseline serositis. This result suggests that, in developing future treatment strategies, that baseline serositis may be treated as an indicator for clinicians to initiate intensive IST for patients with SLE-associated PAH. Although the literature is limited, this result concurs with a recent case report finding that a patient with SLE-associated PAH and high disease activity has totally recovered after methylprednisolone pulse therapy [34] . In another recent study, the use of immunosuppressants was an independent predictor of a short-term response in patients with CTD-associated PAH [35] . The potential clinical significance still needs further investigation and evidence from randomized clinical trials.
This study has several limitations. First, 310 patients were initially enrolled in our study, and patients without information about death or TGA were excluded from the prognosis analyses. Fortunately, there was no significant difference in the baseline characteristics of patients included and excluded in the prognosis analyses (data not shown), indicating the lack of the outcome data was random. Second, we included both the incident and prevalent populations. Patients with incident PAH have poorer survival rates than patients with prevalent disease, according to both the French registry and the Registry to Evaluate
Early and Long-term Pulmonary Arterial Hypertension Disease Management (REVEAL) studies [7, 36] .
Thus, the incident cohort and prevalent cohort need to be studied separately in future studies. Also, we reported that 69.4% patients in our cohort received PAH target medications at baseline, explained by socioeconomic reasons. Thus, the effect of different treatment regimens needs to be further studied. Lastly, there were 31.6% missing value of RAP in our cohort explained by the reason that RAP was not a routinely reported value in some PAH centers. However, it showed some a tendency of predicting death even without significant significance. Future studies need to collect complete information on this value and prove its prognostic significance.
This study is for now the largest prognostic cohort consisting of patients with SLE-associated PAH based on a RHC algorithm. It reported the 1-, 3-and 5-year survival rates of patients with SLE-associated PAH and further identified CI as a predictor of mortality. We reported for the first time the 1-, 3-and 5-year rates of achieving treatment goals. CI, 6MWD and serositis were prognostic factors of TGA. TGA was associated with long-term survival, the first evidence supporting the treat-to target strategy in SLE-associated PAH. Baseline heart function predicted both survival and TGA in patients with SLE-associated PAH. Patients with serositis at baseline tended to benefit from intensive immunosuppressive therapy and to have better clinical outcomes. Further investigation on the therapeutic strategy specific for SLE-associated PAH is urgently needed. Tables   Table 1 Baseline characteristics 
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